Close

Impax Laboratories (IPXL) Misses Q2 EPS by 11c; Guides Lower

Go back to Impax Laboratories (IPXL) Misses Q2 EPS by 11c; Guides Lower

Impax Reports Second Quarter 2016 Financial Results

August 9, 2016 7:01 AM EDT

HAYWARD, Calif., Aug. 9, 2016 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today reported second quarter 2016 financial results for the quarter ended June 30, 2016.

Logo - http://photos.prnewswire.com/prnh/20150310/180590LOGO

Total revenues in the second quarter 2016 declined 19% to $172.6 million, compared to $214.2 million in the prior year period. The decrease was primarily due to a 30% reduction in Generics division revenues which includes the impact of an approximate... More